{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:26:55Z","timestamp":1794414415599,"version":"4.9.1"},"reference-count":315,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,3]],"date-time":"2027-09-03T00:00:00Z","timestamp":1819929600000},"content-version":"am","delay-in-days":276,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031690","name":"Christ University","doi-asserted-by":"publisher","award":["CU:CRP-SC:SM-25\/102"],"award-info":[{"award-number":["CU:CRP-SC:SM-25\/102"]}],"id":[{"id":"10.13039\/100031690","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008271","name":"The University of Oklahoma Health Sciences College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015308","name":"Stephenson Cancer Center","doi-asserted-by":"publisher","award":["P30CA036727"],"award-info":[{"award-number":["P30CA036727"]}],"id":[{"id":"10.13039\/100015308","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.pharmthera.2026.109109","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T23:11:15Z","timestamp":1788045075000},"page":"109109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting metabolic reprogramming in cancer: Past, present, and future"],"prefix":"10.1016","volume":"288","author":[{"given":"Niti","family":"Kumari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra K.","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pharmthera.2026.109109_bib1513","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1038\/s41467-022-32849-1","article-title":"Distinct metabolic states guide maturation of inflammatory and tolerogenic dendritic cells","volume":"13","author":"Adamik","year":"2022","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-026-02583-x","article-title":"Reactive oxygen species (ROS) in cancer: From mechanism to therapeutic implications","volume":"11","author":"Akter","year":"2026","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0010","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S1470-2045(17)30314-5","article-title":"Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: A single-centre, open-label, dose-escalation, phase 1 trial","volume":"18","author":"Alistar","year":"2017","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0015","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nrc.2016.71","article-title":"From Krebs to clinic: Glutamine metabolism to cancer therapy","volume":"16","author":"Altman","year":"2016","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0020","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","article-title":"Metabolic programming and immune suppression in the tumor microenvironment","volume":"41","author":"Arner","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0025","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ni.3838","article-title":"Srebp-controlled glucose metabolism is essential for NK cell functional responses","volume":"18","author":"Assmann","year":"2017","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0030","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/onc.2014.155","article-title":"Ribonucleotide reductase and cancer: Biological mechanisms and targeted therapies","volume":"34","author":"Aye","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0035","doi-asserted-by":"crossref","first-page":"18757","DOI":"10.1074\/jbc.TM118.003336","article-title":"Polyamine synthesis as a target of MYC oncogenes","volume":"293","author":"Bachmann","year":"2018","journal-title":"The Journal of Biological Chemistry"},{"issue":"399\u2013416","key":"10.1016\/j.pharmthera.2026.109109_bb0040","article-title":"Reactivation of dihydroorotate dehydrogenase-driven pyrimidine biosynthesis restores tumor growth of respiration-deficient cancer cells","volume":"29","author":"Bajzikova","year":"2019","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0045","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/bies.20002","article-title":"Hypoxia-inducible factor-1 and oncogenic signalling","volume":"26","author":"Bardos","year":"2004","journal-title":"Bioessays"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0050","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1039\/D0NA01084G","article-title":"The evolution of nucleosidic analogues: Self-assembly of prodrugs into nanoparticles for cancer drug delivery","volume":"3","author":"Baroud","year":"2021","journal-title":"Nanoscale Advances"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0055","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41586-022-05661-6","article-title":"Slow TCA flux and ATP production in primary solid tumours but not metastases","volume":"614","author":"Bartman","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0060","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1172\/JCI89455","article-title":"Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy","volume":"127","author":"Beavis","year":"2017","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0065","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","article-title":"Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses","volume":"3","author":"Beavis","year":"2015","journal-title":"Cancer Immunology Research"},{"issue":"134\u2013149","key":"10.1016\/j.pharmthera.2026.109109_bb0070","article-title":"Microenvironmental ammonia enhances T cell exhaustion in colorectal cancer","volume":"35","author":"Bell","year":"2023","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0075","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1126\/science.1228792","article-title":"Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1","volume":"339","author":"Ben-Sahra","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0080","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","article-title":"The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis","volume":"575","author":"Bersuker","year":"2019","journal-title":"Nature"},{"issue":"874\u2013887","key":"10.1016\/j.pharmthera.2026.109109_bb0085","article-title":"Glutaminase inhibition impairs CD8 T cell activation in STK11\u2212\/Lkb1-deficient lung cancer","volume":"34","author":"Best","year":"2022","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0090","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1006\/bbrc.1997.6835","article-title":"Effect of oncogene transformation of rat embryo cells on cellular oxygen consumption and glycolysis","volume":"235","author":"Biaglow","year":"1997","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0095","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2015.07.016","article-title":"An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis","volume":"162","author":"Birsoy","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0100","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1158\/1535-7163.MCT-22-0721","article-title":"Arginase 1\/2 inhibitor OATD-02: From discovery to first-in-man setup in cancer immunotherapy","volume":"22","author":"Borek","year":"2023","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0105","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0968-0004(00)89097-0","article-title":"A target for phosphoinositide 3-kinase: Akt\/PKB","volume":"20","author":"Bos","year":"1995","journal-title":"Trends in Biochemical Sciences"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0110","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0115","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41591-018-0095-6","article-title":"Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate","volume":"24","author":"Bunse","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0120","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood.V8.11.965.965","article-title":"Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases","volume":"8","author":"Burchenal","year":"1953","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0125","first-page":"305","article-title":"Therapy for acute leukemia in adults with cytosine arabinoside (NSC-63878), vincristine (NSC-67574), and prednisone (NSC-10023)","volume":"52","author":"Burke","year":"1968","journal-title":"Cancer Chemotherapy Reports"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0130","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101249","article-title":"Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence","volume":"32","author":"Cappabianca","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0140","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","article-title":"Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: The phase II NeoCOAST platform trial","volume":"13","author":"Cascone","year":"2023","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0145","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0150","article-title":"Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy","volume":"9","author":"Chen","year":"2023","journal-title":"Science Advances"},{"issue":"961\u2013978","key":"10.1016\/j.pharmthera.2026.109109_bb0155","article-title":"Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8(+) T cells in the tumor microenvironment","volume":"35","author":"Cheng","year":"2023","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0160","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.celrep.2016.09.042","article-title":"Breast cancer-derived lung metastases show increased pyruvate carboxylase-dependent anaplerosis","volume":"17","author":"Christen","year":"2016","journal-title":"Cell Reports"},{"issue":"26","key":"10.1016\/j.pharmthera.2026.109109_bib1525","doi-asserted-by":"crossref","first-page":"39421","DOI":"10.18632\/oncotarget.9820","article-title":"Lymphatic endothelial cells attenuate inflammation via suppression of dendritic cell maturation","volume":"7","author":"Christiansen","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0165","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature06734","article-title":"The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth","volume":"452","author":"Christofk","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0170","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41571-022-00686-2","article-title":"The multiple roles of LDH in cancer","volume":"19","author":"Claps","year":"2022","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0175","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00644-17","article-title":"p62-dependent phase separation of patient-derived KEAP1 mutations and NRF2","volume":"38","author":"Cloer","year":"2018","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0180","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1432-1033.1991.tb16305.x","article-title":"Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families","volume":"201","author":"Coffer","year":"1991","journal-title":"European Journal of Biochemistry"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0185","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumour-associated macrophages by tumour-derived lactic acid","volume":"513","author":"Colegio","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0190","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nature12138","article-title":"Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells","volume":"497","author":"Commisso","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109109_bib1518","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1038\/s41467-020-17750-z","article-title":"Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine","volume":"11","author":"Campesato","year":"2020","journal-title":"Nature Communications"},{"issue":"243\u2013255","key":"10.1016\/j.pharmthera.2026.109109_bb0195","article-title":"Dysfunction of natural killer cells by FBP1-induced inhibition of glycolysis during lung cancer progression","volume":"28","author":"Cong","year":"2018","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0200","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.53618","article-title":"Combined deletion of Glut1 and Glut3 impairs lung adenocarcinoma growth","volume":"9","author":"Contat","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0205","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0304-3835(85)90017-5","article-title":"Oncogene expression in rat hepatomas and during hepatocarcinogenesis","volume":"26","author":"Cote","year":"1985","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0210","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41698-025-01114-1","article-title":"Author correction: Integrative analysis of KEAP1\/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer","volume":"9","author":"Crippa","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0215","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0006-291X(69)90709-8","article-title":"A new pyruvate kinase isozyme in hepatomas","volume":"35","author":"Criss","year":"1969","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0220","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","article-title":"Cellular fatty acid metabolism and cancer","volume":"18","author":"Currie","year":"2013","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0225","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0230","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1023\/A:1022446730452","article-title":"Oncogenes in tumor metabolism, tumorigenesis, and apoptosis","volume":"29","author":"Dang","year":"1997","journal-title":"Journal of Bioenergetics and Biomembranes"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0235","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0240","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1600200","article-title":"Fundamentals of cancer metabolism","volume":"2","author":"DeBerardinis","year":"2016","journal-title":"Science Advances"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0245","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature10189","article-title":"Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis","volume":"475","author":"DeNicola","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0250","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s40265-018-0978-3","article-title":"Ivosidenib: First global approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"issue":"240\u2013256","key":"10.1016\/j.pharmthera.2026.109109_bb0255","article-title":"An embryonic diapause-like adaptation with suppressed Myc activity enables tumor treatment persistence","volume":"39","author":"Dhimolea","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0260","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.addr.2015.12.011","article-title":"Tumor lymphangiogenesis and new drug development","volume":"99","author":"Dieterich","year":"2016","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0265","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abk1023","article-title":"Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition","volume":"7","author":"Ding","year":"2021","journal-title":"Science Advances"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0270","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev-cancerbio-030518-055844","article-title":"The hallmarks of ferroptosis","volume":"3","author":"Dixon","year":"2019","journal-title":"Annual Review of Cancer Biology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0275","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41556-025-01627-8","article-title":"ADSL-generated fumarate binds and inhibits STING to promote tumour immune evasion","volume":"27","author":"Duan","year":"2025","journal-title":"Nature Cell Biology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0280","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2016.08.009","article-title":"One-carbon metabolism in health and disease","volume":"25","author":"Ducker","year":"2017","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0285","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2217\/fon.09.44","article-title":"Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy","volume":"5","author":"Dwarakanath","year":"2009","journal-title":"Future Oncology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0290","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF00216936","article-title":"Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas","volume":"8","author":"Earhart","year":"1990","journal-title":"Investigational New Drugs"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0295","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140100","article-title":"Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer","volume":"131","author":"Edwards","year":"2021","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0300","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1073\/pnas.1417636112","article-title":"Immune-mediated antitumor effect by type 2 diabetes drug, metformin","volume":"112","author":"Eikawa","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0305","first-page":"356","article-title":"Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: A concise literature review and case study","volume":"33","author":"El Sayed","year":"2014","journal-title":"Chinese Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0310","doi-asserted-by":"crossref","first-page":"15267","DOI":"10.1038\/ncomms15267","article-title":"Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells","volume":"8","author":"Elia","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0315","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1158\/0008-5472.CAN-20-4028","article-title":"Macrophage-derived cholesterol contributes to therapeutic resistance in prostate cancer","volume":"81","author":"El-Kenawi","year":"2021","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0320","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1158\/0008-5472.CAN-03-2904","article-title":"Akt stimulates aerobic glycolysis in cancer cells","volume":"64","author":"Elstrom","year":"2004","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0325","first-page":"53","article-title":"Phosphofructokinase: Structure and control","volume":"293","author":"Evans","year":"1981","journal-title":"Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0330","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1128\/MCB.06120-11","article-title":"Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH\/NAD(+) redox homeostasis in cancer cells","volume":"31","author":"Fan","year":"2011","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0335","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1021\/cb500683c","article-title":"Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate","volume":"10","author":"Fan","year":"2015","journal-title":"ACS Chemical Biology"},{"issue":"514\u2013526","key":"10.1016\/j.pharmthera.2026.109109_bb0340","article-title":"Itaconate transporter SLC13A3 confers immunotherapy resistance via alkylation-mediated stabilization of PD-L1","volume":"37","author":"Fan","year":"2025","journal-title":"Cell Metabolism"},{"issue":"1118\u20131133","key":"10.1016\/j.pharmthera.2026.109109_bb0345","article-title":"Methionine restriction promotes cGAS activation and chromatin untethering through demethylation to enhance antitumor immunity","volume":"41","author":"Fang","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0350","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid","volume":"238","author":"Farber","year":"1948","journal-title":"The New England Journal of Medicine"},{"issue":"358\u2013371","key":"10.1016\/j.pharmthera.2026.109109_bb0355","article-title":"Lactate metabolism in human lung tumors","volume":"171","author":"Faubert","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0360","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw5473","article-title":"Metabolic reprogramming and cancer progression","volume":"368","author":"Faubert","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0365","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: An international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217680","article-title":"The arginine metabolism and its deprivation in cancer therapy","volume":"620","author":"Feng","year":"2025","journal-title":"Cancer Letters"},{"issue":"3405\u20133420","key":"10.1016\/j.pharmthera.2026.109109_bb0375","article-title":"CD36-mediated metabolic rewiring of breast cancer cells promotes resistance to HER2-targeted therapies","volume":"29","author":"Feng","year":"2019","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0380","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.145207","article-title":"Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade","volume":"6","author":"Ferrere","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0390","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/2767-9764.CRC-23-0249","article-title":"Dual blockade of EP2 and EP4 signaling is required for optimal immune activation and antitumor activity against prostaglandin-expressing tumors","volume":"3","author":"Francica","year":"2023","journal-title":"Cancer Research Communications"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0395","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s43018-021-00201-z","article-title":"Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas","volume":"2","author":"Friedrich","year":"2021","journal-title":"Nature Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0400","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0405","doi-asserted-by":"crossref","first-page":"16047","DOI":"10.1038\/cddiscovery.2016.47","article-title":"Glucose- and glutamine-fueled stabilization of C-Myc is required for T-cell proliferation and malignant transformation","volume":"2","author":"Gabriel","year":"2016","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0410","first-page":"2941","article-title":"Malnutrition and cachexia in ovarian cancer patients: Pathophysiology and management","volume":"21","author":"Gadducci","year":"2001","journal-title":"Anticancer Research"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0415","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature07823","article-title":"c-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism","volume":"458","author":"Gao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0420","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114351","article-title":"YAP\/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis","volume":"13","author":"Gao","year":"2021","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0425","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7527996","article-title":"ATF4\/MYC regulates MTHFD2 to promote NSCLC progression by mediating redox homeostasis","volume":"2022","author":"Gao","year":"2022","journal-title":"Disease Markers"},{"issue":"1774\u20131787","key":"10.1016\/j.pharmthera.2026.109109_bb0430","article-title":"Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance","volume":"41","author":"Gjuka","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0435","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/s42255-023-00856-1","article-title":"Asparagine restriction enhances CD8(+) T cell metabolic fitness and antitumoral functionality through an NRF2-dependent stress response","volume":"5","author":"Gnanaprakasam","year":"2023","journal-title":"Nature Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0440","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13073-022-01146-3","article-title":"Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape","volume":"14","author":"Golkaram","year":"2022","journal-title":"Genome Medicine"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0445","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cmet.2020.01.015","article-title":"AMPK and TOR: The Yin and Yang of cellular nutrient sensing and growth control","volume":"31","author":"Gonzalez","year":"2020","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0450","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109109_bib1516","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.it.2025.02.015","article-title":"The unusual metabolism of germinal center B cells","volume":"46","author":"Gracie","year":"2025","journal-title":"Trends in Immunology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2020.118913","article-title":"NCOA4-mediated ferritinophagy promotes ferroptosis induced by erastin, but not by RSL3 in HeLa cells","volume":"1868","author":"Gryzik","year":"2021","journal-title":"Biochimica et Biophysica Acta, Molecular Cell Research"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110986","article-title":"Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-beta signaling in regulatory T cells","volume":"39","author":"Gu","year":"2022","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0465","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1084\/jem.20161087","article-title":"Fumarate hydratase is a critical metabolic regulator of hematopoietic stem cell functions","volume":"214","author":"Guitart","year":"2017","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0470","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41586-023-06299-8","article-title":"SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity","volume":"620","author":"Guo","year":"2023","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109109_bib1520","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002202","article-title":"Lactate regulates metabolic and pro-inflammatory circuits in control of t cell migration and effector functions","volume":"13","author":"Haas","year":"2015","journal-title":"PLOS Biology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0475","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S0021-9258(18)64337-6","article-title":"Relation of folic acid reductase to amethopterin resistance in cultured mammalian cells","volume":"236","author":"Hakala","year":"1961","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0480","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccell.2015.12.004","article-title":"An integrated metabolic atlas of clear cell renal cell carcinoma","volume":"29","author":"Hakimi","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0485","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","article-title":"A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer","volume":"29","author":"Halford","year":"2023","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0490","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s00210-025-04635-5","article-title":"CAF-derived exosomes: Orchestrators of dysregulated signaling pathways in breast cancer progression","volume":"399","author":"Hameed","year":"2026","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0495","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0500","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2026.109109_bib1521","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.canlet.2020.12.021","article-title":"The oncogenic and clinical implications of lactate induced immunosuppression in the tumour microenvironment","volume":"500","author":"Hayes","year":"2021","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0505","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-025-02340-8","article-title":"Systemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer","volume":"25","author":"He","year":"2026","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0510","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-23-0334","article-title":"Vitamin B6 competition in the tumor microenvironment hampers antitumor functions of NK cells","volume":"14","author":"He","year":"2024","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0515","doi-asserted-by":"crossref","first-page":"41422","DOI":"10.18632\/oncotarget.17440","article-title":"P53 suppresses ribonucleotide reductase via inhibiting mTORC1","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0520","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41586-025-09303-5","article-title":"NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity","volume":"645","author":"Heide","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0525","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/179663a0","article-title":"Fluorinated pyrimidines, a new class of tumour-inhibitory compounds","volume":"179","author":"Heidelberger","year":"1957","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0530","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.mam.2018.02.003","article-title":"Redox control in cancer development and progression","volume":"63","author":"Helfinger","year":"2018","journal-title":"Molecular Aspects of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0535","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.22.00227","article-title":"COAST: An open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung Cancer","volume":"40","author":"Herbst","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109109_bib1512","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13046-026-03644-3","article-title":"Tertiary lymphoid structures in the era of cancer therapy","volume":"45","author":"Hern\u00e1ndez-Verdin","year":"2026","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0540","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0545","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41568-021-00388-4","article-title":"Tumour fatty acid metabolism in the context of therapy resistance and obesity","volume":"21","author":"Hoy","year":"2021","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0550","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1177\/1535370219870771","article-title":"The role of cholesterol and cholesterol-driven membrane raft domains in prostate cancer","volume":"244","author":"Hryniewicz-Jankowska","year":"2019","journal-title":"Experimental Biology and Medicine (Maywood, N.J.)"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0555","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41556-021-00820-9","article-title":"Cancer-cell-derived GABA promotes beta-catenin-mediated tumour growth and immunosuppression","volume":"24","author":"Huang","year":"2022","journal-title":"Nature Cell Biology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0560","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature24057","article-title":"Glucose feeds the TCA cycle via circulating lactate","volume":"551","author":"Hui","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109109_bb0565","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41420-026-03063-5","article-title":"Lactate-mediated NK cell dysfunction as a prognostic marker and therapeutic target in breast cancer","volume":"12","author":"Ielpo","year":"2026","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0570","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.cmet.2015.06.023","article-title":"Hypoxia induces production of L-2-hydroxyglutarate","volume":"22","author":"Intlekofer","year":"2015","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0575","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.canlet.2021.09.007","article-title":"Metabolic shift to serine biosynthesis through 3-PG accumulation and PHGDH induction promotes tumor growth in pancreatic cancer","volume":"523","author":"Itoyama","year":"2021","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0580","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1089\/ars.2019.7902","article-title":"2-hydroxyglutarate in cancer cells","volume":"33","author":"Jezek","year":"2020","journal-title":"Antioxidants & Redox Signaling"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0585","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nature17393","article-title":"Reductive carboxylation supports redox homeostasis during anchorage-independent growth","volume":"532","author":"Jiang","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105217","article-title":"GABA-mediated inhibition of human CD4(+) T cell functions is enhanced by insulin but impaired by high glucose levels","volume":"105","author":"Jin","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0595","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/s12276-020-00539-x","article-title":"Histone acylation marks respond to metabolic perturbations and enable cellular adaptation","volume":"52","author":"Jo","year":"2020","journal-title":"Experimental & Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0600","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41392-020-00326-0","article-title":"NADPH homeostasis in cancer: Functions, mechanisms and therapeutic implications","volume":"5","author":"Ju","year":"2020","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0605","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41586-018-0316-7","article-title":"Histidine catabolism is a major determinant of methotrexate sensitivity","volume":"559","author":"Kanarek","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0610","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bbrc.2017.06.192","article-title":"The regulation of tumor cell physiology by mitochondrial dynamics","volume":"500","author":"Kashatus","year":"2018","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0615","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1158\/1078-0432.CCR-22-2807","article-title":"Phase II investigation of TVB-2640 (Denifanstat) with bevacizumab in patients with first relapse high-grade astrocytoma","volume":"29","author":"Kelly","year":"2023","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0620","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cmet.2006.02.002","article-title":"HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia","volume":"3","author":"Kim","year":"2006","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0625","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1128\/MCB.24.13.5923-5936.2004","article-title":"Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays","volume":"24","author":"Kim","year":"2004","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0630","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s12276-026-01650-1","article-title":"Metabolic crosstalk among cancer-associated fibroblasts, adipocytes and immune cells as an immunosuppressive tumor microenvironment driver","volume":"58","author":"Kim","year":"2026","journal-title":"Experimental & Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0635","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1126\/science.2814477","article-title":"Human cells lacking mtDNA: Repopulation with exogenous mitochondria by complementation","volume":"246","author":"King","year":"1989","journal-title":"Science"},{"issue":"2269\u20132287","key":"10.1016\/j.pharmthera.2026.109109_bb0640","article-title":"A glycolytic metabolite bypasses \u201ctwo-hit\u201d tumor suppression by BRCA2","volume":"187","author":"Kong","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0645","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40880-018-0288-x","article-title":"Amino acid transporter SLC7A11\/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer","volume":"38","author":"Koppula","year":"2018","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0650","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nature20132","article-title":"LKB1 loss links serine metabolism to DNA methylation and tumorigenesis","volume":"539","author":"Kottakis","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0655","doi-asserted-by":"crossref","first-page":"11457","DOI":"10.1038\/ncomms11457","article-title":"Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor","volume":"7","author":"Krall","year":"2016","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0660","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41586-024-07254-x","article-title":"PGE(2) limits effector expansion of tumour-infiltrating stem-like CD8(+) T cells","volume":"629","author":"Lacher","year":"2024","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109109_bib1519","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41577-025-01263-1","article-title":"Tumour lactate bars B cell entry","volume":"26","author":"Lamorte","year":"2026","journal-title":"Nature Reviews Immunology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0665","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1186\/s12885-023-10971-7","article-title":"A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679\/ECHO-302)","volume":"23","author":"Lara","year":"2024","journal-title":"BMC Cancer"},{"issue":"992\u20131003","key":"10.1016\/j.pharmthera.2026.109109_bb0670","first-page":"1001","article-title":"PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis","volume":"16","author":"LeBleu","year":"2014","journal-title":"Nature Cell Biology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0675","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1158\/1078-0432.CCR-22-0061","article-title":"Telaglenastat plus everolimus in advanced renal cell carcinoma: A randomized, double-blinded, placebo-controlled, phase II ENTRATA trial","volume":"28","author":"Lee","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0680","doi-asserted-by":"crossref","first-page":"32433","DOI":"10.1073\/pnas.2006828117","article-title":"Polyunsaturated fatty acid biosynthesis pathway determines ferroptosis sensitivity in gastric cancer","volume":"117","author":"Lee","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0685","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148550","article-title":"Clinical development of metabolic inhibitors for oncology","volume":"132","author":"Lemberg","year":"2022","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0690","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41568-020-0273-y","article-title":"Metabolism of immune cells in cancer","volume":"20","author":"Leone","year":"2020","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0695","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1126\/science.aav2588","article-title":"Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion","volume":"366","author":"Leone","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0700","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41571-019-0203-7","article-title":"Navigating metabolic pathways to enhance antitumour immunity and immunotherapy","volume":"16","author":"Li","year":"2019","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0705","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1074374","article-title":"Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity","volume":"5","author":"Li","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0710","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1158\/1078-0432.CCR-22-0612","article-title":"Phase Ia\/b, open-label, multicenter study of AZD4635 (an adenosine A2A receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors","volume":"28","author":"Lim","year":"2022","journal-title":"Clinical Cancer Research"},{"issue":"2032\u20132044","key":"10.1016\/j.pharmthera.2026.109109_bb0715","article-title":"Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance","volume":"42","author":"Lin","year":"2024","journal-title":"Cancer Cell"},{"issue":"984\u2013999","key":"10.1016\/j.pharmthera.2026.109109_bb0720","article-title":"QDPR deficiency drives immune suppression in pancreatic cancer","volume":"36","author":"Liu","year":"2024","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0725","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2147\/CMAR.S421771","article-title":"Role of human monocarboxylate transporter 1 (hMCT1) and 4 (hMCT4) in tumor cells and the tumor microenvironment","volume":"15","author":"Liu","year":"2023","journal-title":"Cancer Management and Research"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0730","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1038\/s41467-018-06841-7","article-title":"Nuclear lactate dehydrogenase A senses ROS to produce alpha-hydroxybutyrate for HPV-induced cervical tumor growth","volume":"9","author":"Liu","year":"2018","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0735","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002722","article-title":"Global regulation of nucleotide biosynthetic genes by c-Myc","volume":"3","author":"Liu","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0740","article-title":"CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing","volume":"120","author":"Liu","year":"2023","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0745","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nrc3557","article-title":"Serine, glycine and one-carbon units: cancer metabolism in full circle","volume":"13","author":"Locasale","year":"2013","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0750","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/s41418-018-0227-z","article-title":"Mutant p53-dependent mitochondrial metabolic alterations in a mesenchymal stem cell-based model of progressive malignancy","volume":"26","author":"Lonetto","year":"2019","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0755","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): A phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0760","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.tips.2009.11.004","article-title":"Calorie restriction and cancer prevention: Metabolic and molecular mechanisms","volume":"31","author":"Longo","year":"2010","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0765","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006522","article-title":"Metabolic reprogramming via an engineered PGC-1alpha improves human chimeric antigen receptor T-cell therapy against solid tumors","volume":"11","author":"Lontos","year":"2023","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0770","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006287","article-title":"Inhibition of lactate transport by MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell malignancies","volume":"11","author":"Lopez","year":"2023","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0775","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/s41416-023-02204-2","article-title":"Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?","volume":"128","author":"Lord","year":"2023","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0780","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1101\/gad.217406.113","article-title":"What a difference a hydroxyl makes: Mutant IDH, (R)-2-hydroxyglutarate, and cancer","volume":"27","author":"Losman","year":"2013","journal-title":"Genes & Development"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0785","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s41568-020-00303-3","article-title":"2-Oxoglutarate-dependent dioxygenases in cancer","volume":"20","author":"Losman","year":"2020","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0790","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abj4220","article-title":"Metabolite activation of tumorigenic signaling pathways in the tumor microenvironment","volume":"15","author":"Low","year":"2022","journal-title":"Science Signaling"},{"issue":"2021\u20132035","key":"10.1016\/j.pharmthera.2026.109109_bb0795","article-title":"Ketolysis drives CD8(+) T cell effector function through effects on histone acetylation","volume":"56","author":"Luda","year":"2023","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109109_bib1526","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.celrep.2012.01.005","article-title":"VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics","volume":"1","author":"Lund","year":"2012","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0800","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cell.2011.03.054","article-title":"Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1","volume":"145","author":"Luo","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0805","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41420-025-02767-4","article-title":"Glutamine: A new strategy for targeted metabolic therapy in the tumor microenvironment","volume":"11","author":"Lv","year":"2025","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0810","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00000421-198210000-00014","article-title":"Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma","volume":"5","author":"Lynch","year":"1982","journal-title":"American Journal of Clinical Oncology"},{"issue":"143\u2013156","key":"10.1016\/j.pharmthera.2026.109109_bb0815","article-title":"Cholesterol induces CD8(+) T cell exhaustion in the tumor microenvironment","volume":"30","author":"Ma","year":"2019","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0820","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.bbrc.2018.02.097","article-title":"Lipid metabolism and lipophagy in cancer","volume":"504","author":"Maan","year":"2018","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0825","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature11743","article-title":"Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells","volume":"493","author":"Maddocks","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0830","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1158\/2159-8290.CD-20-1114","article-title":"RB\/E2F1 as a master regulator of cancer cell metabolism in advanced disease","volume":"11","author":"Mandigo","year":"2021","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0835","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","article-title":"DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer","volume":"593","author":"Mao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.115064","article-title":"Metabolic reprogramming, sensing, and cancer therapy","volume":"43","author":"Mao","year":"2024","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0845","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/modpathol.2013.86","article-title":"Succinate dehydrogenase deficiency is associated with decreased 5-hydroxymethylcytosine production in gastrointestinal stromal tumors: Implications for mechanisms of tumorigenesis","volume":"26","author":"Mason","year":"2013","journal-title":"Modern Pathology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0850","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0855","doi-asserted-by":"crossref","first-page":"6244","DOI":"10.1016\/S0021-9258(20)81851-1","article-title":"Differences in phosphofructokinase regulation in normal and tumor rat thyroid cells","volume":"251","author":"Meldolesi","year":"1976","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0860","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature10602","article-title":"Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia","volume":"481","author":"Metallo","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0865","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1242\/jcs.1985.Supplement_3.19","article-title":"Early response pattern analysis of the mitogenic pathway in lymphocytes and fibroblasts","volume":"3","author":"Metcalfe","year":"1985","journal-title":"Journal of Cell Science. Supplement"},{"issue":"527\u2013541","key":"10.1016\/j.pharmthera.2026.109109_bb0870","article-title":"Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer","volume":"55","author":"Meylan","year":"2022","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109109_bib1514","doi-asserted-by":"crossref","DOI":"10.1093\/discim\/kyad006","article-title":"The link between T cell activation and development of functionally useful tumour-associated high endothelial venules","volume":"2","author":"Milutinovic","year":"2023","journal-title":"Discovery Immunology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0875","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-022-05022-3","article-title":"A non-canonical vitamin K cycle is a potent ferroptosis suppressor","volume":"608","author":"Mishima","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0880","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0885","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrc3398","article-title":"Ceramide-orchestrated signalling in cancer cells","volume":"13","author":"Morad","year":"2013","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0890","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-024-07352-w","article-title":"PGE(2) inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function","volume":"629","author":"Morotti","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0895","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41568-023-00557-7","article-title":"Nucleotide metabolism: a pan-cancer metabolic dependency","volume":"23","author":"Mullen","year":"2023","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0900","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41418-022-01096-8","article-title":"Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation","volume":"30","author":"Muller","year":"2023","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0905","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1158\/0008-5472.CAN-23-2742","article-title":"Ketogenic diet alters the epigenetic and immune landscape of prostate cancer to overcome resistance to immune checkpoint blockade therapy","volume":"84","author":"Murphy","year":"2024","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0910","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41556-024-01372-4","article-title":"Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 axis","volume":"26","author":"Murthy","year":"2024","journal-title":"Nature Cell Biology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0915","doi-asserted-by":"crossref","DOI":"10.1136\/bmjonc-2023-000249","article-title":"First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours","volume":"3","author":"Naing","year":"2024","journal-title":"BMJ Oncology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0920","first-page":"9","article-title":"Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer","author":"Nam","year":"2021","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0925","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006070","article-title":"Metabolic imaging of patients with prostate cancer using hyperpolarized [1-(1)(3)C]pyruvate","volume":"5","author":"Nelson","year":"2013","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0930","first-page":"31","article-title":"Malignant transformation of mammalian cells in culture: Delineation of stages and role of cellular oncogene activation","volume":"67","author":"Newbold","year":"1985","journal-title":"IARC Scientific Publications"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0935","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1101\/gad.264127.115","article-title":"Proteomic analysis of pRb loss highlights a signature of decreased mitochondrial oxidative phosphorylation","volume":"29","author":"Nicolay","year":"2015","journal-title":"Genes & Development"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0940","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ccr.2005.03.036","article-title":"Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation","volume":"7","author":"Nilsson","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0945","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1038\/ncomms4128","article-title":"Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer","volume":"5","author":"Nilsson","year":"2014","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0950","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi8602","article-title":"Lactate supports a metabolic-epigenetic link in macrophage polarization","volume":"7","author":"Noe","year":"2021","journal-title":"Science Advances"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0955","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2026.109109_bib1523","doi-asserted-by":"crossref","first-page":"627647","DOI":"10.3389\/fcell.2020.627647","article-title":"Molecular mechanisms controlling lymphatic Endothelial Junction Integrity","volume":"8","author":"Norden","year":"2021","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0960","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/1078-0432.CCR-18-3749","article-title":"FDA approval summary: Ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation","volume":"25","author":"Norsworthy","year":"2019","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0965","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41586-023-06073-w","article-title":"Uridine-derived ribose fuels glucose-restricted pancreatic cancer","volume":"618","author":"Nwosu","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0970","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3389\/fimmu.2017.01300","article-title":"Pyruvate kinase M2 is required for the expression of the immune checkpoint PD-L1 in immune cells and tumors","volume":"8","author":"Palsson-McDermott","year":"2017","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0975","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0980","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0006-291X(62)90134-1","article-title":"Phosphofructokinase and the Pasteur effect","volume":"7","author":"Passonneau","year":"1962","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0985","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ccr.2013.06.014","article-title":"Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer","volume":"24","author":"Patra","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0990","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.4161\/cc.8.23.10238","article-title":"The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma","volume":"8","author":"Pavlides","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.pharmthera.2026.109109_bb0995","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1000","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: Still emerging","volume":"34","author":"Pavlova","year":"2022","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1005","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/s41590-024-01999-3","article-title":"Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism","volume":"25","author":"Peralta","year":"2024","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1010","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1200\/JCO.23.02659","article-title":"Devimistat (CPI-613) with modified fluorouarcil, oxaliplatin, irinotecan, and leucovorin (FFX) versus FFX for patients with metastatic adenocarcinoma of the pancreas: The phase III AVENGER 500 study","volume":"42","author":"Philip","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105576","article-title":"Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: A dual-agent approach targeting immunosuppressive polyamine metabolism","volume":"10","author":"Piha-Paul","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1020","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1025","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.tcb.2023.05.003","article-title":"Regulation of ferroptosis by lipid metabolism","volume":"33","author":"Pope","year":"2023","journal-title":"Trends in Cell Biology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1030","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/bjc.1989.51","article-title":"Phase II study of lonidamine in metastatic breast cancer","volume":"59","author":"Pronzato","year":"1989","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1035","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1073\/pnas.82.11.3535","article-title":"Glycolysis and methylaminoisobutyrate uptake in rat-1 cells transfected with ras or myc oncogenes","volume":"82","author":"Racker","year":"1985","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1040","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1016\/j.celrep.2017.08.066","article-title":"Genome-scale architecture of small molecule regulatory networks and the fundamental trade-off between regulation and enzymatic activity","volume":"20","author":"Reznik","year":"2017","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1045","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1344891","article-title":"Ketogenic diet enhances the anti-cancer effects of PD-L1 blockade in renal cell carcinoma","volume":"15","author":"Richard","year":"2024","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109109_bib1522","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1158\/2326-6066.CIR-21-0778","article-title":"Tumor-derived lactic acid modulates activation and metabolic status of draining lymph node stroma","volume":"10","author":"Riedel","year":"2022","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1050","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/nm.4407","article-title":"Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis","volume":"23","author":"Romero","year":"2017","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1060","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41392-024-01969-z","article-title":"Iron homeostasis and ferroptosis in human diseases: Mechanisms and therapeutic prospects","volume":"9","author":"Ru","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1065","first-page":"81","article-title":"Various isozyme gene expression patterns among human colorectal adenocarcinoma cell lines and tissues","volume":"68","author":"Rutzky","year":"1982","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1070","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41565-021-01000-4","article-title":"Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells","volume":"17","author":"Saha","year":"2022","journal-title":"Nature Nanotechnology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1075","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg3736","article-title":"Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy","volume":"9","author":"Sarkar","year":"2023","journal-title":"Science Advances"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1080","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1085","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/343140a0","article-title":"Structural basis of the allosteric behaviour of phosphofructokinase","volume":"343","author":"Schirmer","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1090","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1158\/0008-5472.CAN-03-0846","article-title":"The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression","volume":"64","author":"Schwartzenberg-Bar-Yoseph","year":"2004","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1095","first-page":"601","article-title":"Chemotherapy with hydroxyurea, leucopheresis and splenectomy in the treatment of chronic myeloid leukemia at the problastic phase","volume":"57","author":"Schwarzenberg","year":"1972","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1100","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature19353","article-title":"Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition","volume":"537","author":"Sciacovelli","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1105","doi-asserted-by":"crossref","first-page":"11635","DOI":"10.1038\/ncomms11635","article-title":"HIF-1alpha-PDK1 axis-induced active glycolysis plays an essential role in macrophage migratory capacity","volume":"7","author":"Semba","year":"2016","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1110","first-page":"5447","article-title":"A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation","volume":"12","author":"Semenza","year":"1992","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1115","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1073\/pnas.0308061100","article-title":"The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress","volume":"101","author":"Shaw","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1120","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2478\/jtim-2022-0022","article-title":"Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinoma","volume":"11","author":"Shen","year":"2023","journal-title":"Jouranl of Translational Internal Medicine"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1125","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1038\/s41467-022-33285-x","article-title":"USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer","volume":"13","author":"Shi","year":"2022","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1130","doi-asserted-by":"crossref","first-page":"14445","DOI":"10.1038\/s41598-018-32659-w","article-title":"Maintenance DFMO increases survival in high risk neuroblastoma","volume":"8","author":"Sholler","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1135","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2049-3002-2-18","article-title":"Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia","volume":"2","author":"Shukla","year":"2014","journal-title":"Cancer & Metabolism"},{"issue":"71\u201387","key":"10.1016\/j.pharmthera.2026.109109_bb1140","article-title":"MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer","volume":"32","author":"Shukla","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1145","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature12040","article-title":"Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway","volume":"496","author":"Son","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1150","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.intimp.2011.02.005","article-title":"L-kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species","volume":"11","author":"Song","year":"2011","journal-title":"International Immunopharmacology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1155","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature19084","article-title":"Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion","volume":"536","author":"Sousa","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1160","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1111\/febs.16248","article-title":"Cytosolic localization and in vitro assembly of human de novo thymidylate synthesis complex","volume":"289","author":"Spizzichino","year":"2022","journal-title":"The FEBS Journal"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1165","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40425-017-0308-4","article-title":"Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment","volume":"5","author":"Steggerda","year":"2017","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1170","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1175","article-title":"PROTAC-mediated HMGCR depletion reprograms lipid metabolism in breast cancer to potentiate photoimmunotherapy via ferroptosis","volume":"13","author":"Su","year":"2026","journal-title":"Advanced Science (Weinh)"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1180","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4049\/jimmunol.1701041","article-title":"Metabolic barriers to T cell function in tumors","volume":"200","author":"Sugiura","year":"2018","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1185","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1172\/JCI69589","article-title":"Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function","volume":"123","author":"Sukumar","year":"2013","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1190","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/2049-3002-2-17","article-title":"Mitochondrial reactive oxygen species and cancer","volume":"2","author":"Sullivan","year":"2014","journal-title":"Cancer & Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1195","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cell.2015.07.017","article-title":"Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells","volume":"162","author":"Sullivan","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1200","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1038\/s41467-023-38360-5","article-title":"Spatially resolved multi-omics highlights cell-specific metabolic remodeling and interactions in gastric cancer","volume":"14","author":"Sun","year":"2023","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1205","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.1073\/pnas.1002459107","article-title":"Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species","volume":"107","author":"Suzuki","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1210","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cmet.2014.12.003","article-title":"Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA","volume":"21","author":"Tan","year":"2015","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1215","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2022.3511","article-title":"Efficacy and safety of telaglenastat plus cabozantinib vs placebo plus cabozantinib in patients with advanced renal cell carcinoma: The CANTATA randomized clinical trial","volume":"8","author":"Tannir","year":"2022","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1220","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/ncb3272","article-title":"Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma","volume":"17","author":"Tardito","year":"2015","journal-title":"Nature Cell Biology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1225","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.tips.2024.04.007","article-title":"Emerging targets in lipid metabolism for cancer therapy","volume":"45","author":"Terry","year":"2024","journal-title":"Trends in Pharmacological Sciences"},{"issue":"2060\u20132076","key":"10.1016\/j.pharmthera.2026.109109_bb1230","article-title":"CD36 maintains lipid homeostasis via selective uptake of monounsaturated fatty acids during matrix detachment and tumor progression","volume":"35","author":"Terry","year":"2023","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1235","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.tcb.2025.04.007","article-title":"Tumor-stromal metabolic crosstalk in pancreatic cancer","volume":"35","author":"Thakur","year":"2025","journal-title":"Trends in Cell Biology"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109109_bb1240","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1158\/0008-5472.CAN-24-1984","article-title":"KRAS signaling inhibition induces a targetable metabolic dependency on lipophagy-dependent fatty acid oxidation in pancreatic cancer","volume":"86","author":"Thakur","year":"2026","journal-title":"Cancer Research"},{"issue":"558\u2013567","key":"10.1016\/j.pharmthera.2026.109109_bb1245","article-title":"Cell-intrinsic glycogen metabolism supports early glycolytic reprogramming required for dendritic cell immune responses","volume":"26","author":"Thwe","year":"2017","journal-title":"Cell Metabolism"},{"issue":"3602\u20133618","key":"10.1016\/j.pharmthera.2026.109109_bb1250","article-title":"De novo and salvage purine synthesis pathways across tissues and tumors","volume":"187","author":"Tran","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1260","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1749-6632.1984.tb37131.x","article-title":"Oncogene research: Closing in on a better understanding of cancer causation","volume":"437","author":"Tronick","year":"1984","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1265","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/2159-8290.CD-24-1409","article-title":"PLT012, a humanized CD36-blocking antibody, is effective for unleashing antitumor immunity against liver cancer and liver metastasis","volume":"15","author":"Tzeng","year":"2025","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1270","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41586-020-2623-z","article-title":"Lymph protects metastasizing melanoma cells from ferroptosis","volume":"585","author":"Ubellacker","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1275","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: The metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1280","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","article-title":"Understanding the intersections between metabolism and cancer biology","volume":"168","author":"Vander Heiden","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1285","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1113\/JP278810","article-title":"Revisiting the Warburg effect: Historical dogma versus current understanding","volume":"599","author":"Vaupel","year":"2021","journal-title":"The Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1290","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2159-8290.CD-21-0030","article-title":"Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in patients with cancer","volume":"12","author":"Vernieri","year":"2022","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1295","doi-asserted-by":"crossref","DOI":"10.1038\/s41389-026-00608-2","article-title":"The oncogenic control of nucleotide synthesis","volume":"15","author":"Vidal-Cruchez","year":"2026","journal-title":"Oncogenesis"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1300","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1038\/s41598-023-31759-6","article-title":"Pan-cancer genomic analysis shows hemizygous PTEN loss tumors are associated with immune evasion and poor outcome","volume":"13","author":"Vidotto","year":"2023","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1305","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrc.2017.86","article-title":"Targeting immunosuppressive adenosine in cancer","volume":"17","author":"Vijayan","year":"2017","journal-title":"Nature Reviews. Cancer"},{"issue":"629\u2013648","key":"10.1016\/j.pharmthera.2026.109109_bb1310","first-page":"ix","article-title":"The antifolates","volume":"26","author":"Visentin","year":"2012","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1315","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nature23007","article-title":"Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway","volume":"547","author":"Viswanathan","year":"2017","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109109_bib1524","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.trecan.2025.04.008","article-title":"Tumor-draining lymph nodes - friend or foe during immune checkpoint therapy?","volume":"11","author":"von Renesse","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1320","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrc2715","article-title":"p53 and metabolism","volume":"9","author":"Vousden","year":"2009","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1325","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrc3365","article-title":"Mitochondria and cancer","volume":"12","author":"Wallace","year":"2012","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1330","article-title":"Moonlighting functions of phosphoglycerate dehydrogenase in cancer","volume":"44","author":"Wang","year":"2025","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1335","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1021\/acs.jmedchem.5c02659","article-title":"Dual PARP\/NAMPT inhibitors for BRCA wild-type triple-negative breast cancer: Disrupting homologous recombination repair and activating antitumor immunity","volume":"69","author":"Wang","year":"2026","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1340","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.tcb.2023.03.013","article-title":"The Warburg effect: A signature of mitochondrial overload","volume":"33","author":"Wang","year":"2023","journal-title":"Trends in Cell Biology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1345","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1350","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","article-title":"Metabolic support of tumour-infiltrating regulatory T cells by lactic acid","volume":"591","author":"Watson","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1355","first-page":"2583","article-title":"Marker for renal cell carcinoma (RCC): The dimeric form of pyruvate kinase type M2 (Tu M2-PK)","volume":"19","author":"Wechsel","year":"1999","journal-title":"Anticancer Research"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1360","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41419-018-0330-6","article-title":"Downregulation of SREBP inhibits tumor growth and initiation by altering cellular metabolism in colon cancer","volume":"9","author":"Wen","year":"2018","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1365","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.tibs.2010.05.003","article-title":"Glutamine addiction: A new therapeutic target in cancer","volume":"35","author":"Wise","year":"2010","journal-title":"Trends in Biochemical Sciences"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1370","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1152\/physrev.00035.2018","article-title":"Metabolomics for investigating physiological and pathophysiological processes","volume":"99","author":"Wishart","year":"2019","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1375","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1038\/s41467-023-42634-3","article-title":"Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1alpha-mediated glycolytic reprogramming","volume":"14","author":"Wu","year":"2023","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1380","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41556-020-00615-4","article-title":"Asparagine enhances LCK signalling to potentiate CD8(+) T-cell activation and anti-tumour responses","volume":"23","author":"Wu","year":"2021","journal-title":"Nature Cell Biology"},{"issue":"1580\u20131596","key":"10.1016\/j.pharmthera.2026.109109_bb1385","article-title":"Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-alpha","volume":"35","author":"Wu","year":"2023","journal-title":"Cell Metabolism"},{"issue":"1561\u20131577","key":"10.1016\/j.pharmthera.2026.109109_bb1390","article-title":"Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8(+) T cells in tumors","volume":"54","author":"Xu","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1395","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1400","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1038\/s41467-023-40314-w","article-title":"Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment","volume":"14","author":"Xue","year":"2023","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1405","doi-asserted-by":"crossref","first-page":"11067","DOI":"10.1093\/nar\/gkab871","article-title":"Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair","volume":"49","author":"Yang","year":"2021","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1410","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","article-title":"Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: Phase I trials","volume":"29","author":"Yap","year":"2023","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1415","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/2159-8290.CD-14-0250","article-title":"Serine catabolism regulates mitochondrial redox control during hypoxia","volume":"4","author":"Ye","year":"2014","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1420","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","article-title":"Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism","volume":"149","author":"Ying","year":"2012","journal-title":"Cell"},{"issue":"1147\u20131160","key":"10.1016\/j.pharmthera.2026.109109_bb1425","article-title":"One-carbon metabolism supports S-adenosylmethionine and histone methylation to drive inflammatory macrophages","volume":"75","author":"Yu","year":"2019","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1430","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41590-020-0793-3","article-title":"Disturbed mitochondrial dynamics in CD8(+) TILs reinforce T cell exhaustion","volume":"21","author":"Yu","year":"2020","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1435","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1126\/science.aah5072","article-title":"Adrenergic nerves activate an angio-metabolic switch in prostate cancer","volume":"358","author":"Zahalka","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1440","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41586-023-05770-w","article-title":"Fumarate induces vesicular release of mtDNA to drive innate immunity","volume":"615","author":"Zecchini","year":"2023","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109109_bib1511","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1445","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nature Cell Biology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1450","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1038\/s41423-021-00710-y","article-title":"ENO1 promotes antitumor immunity by destabilizing PD-L1 in NSCLC","volume":"18","author":"Zhang","year":"2021","journal-title":"Cellular & Molecular Immunology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1455","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","article-title":"Metabolic regulation of gene expression by histone lactylation","volume":"574","author":"Zhang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1460","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.111846","article-title":"Lactic acid promotes macrophage polarization through MCT-HIF1alpha signaling in gastric cancer","volume":"388","author":"Zhang","year":"2020","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1465","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/bs.acr.2021.03.009","article-title":"Reductive stress in cancer","volume":"152","author":"Zhang","year":"2021","journal-title":"Advances in Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1470","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41420-024-01933-4","article-title":"Potential role of lipophagy impairment for anticancer effects of glycolysis-suppressed pancreatic ductal adenocarcinoma cells","volume":"10","author":"Zhang","year":"2024","journal-title":"Cell Death Discov"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109109_bib1517","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12916-025-04037-7","article-title":"The impact of metabolic reprogramming on tertiary lymphoid structure formation: Enhancing cancer immunotherapy","volume":"23","author":"Zhang","year":"2025","journal-title":"BMC Medicine"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1475","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/s42255-022-00676-9","article-title":"Myeloid-derived itaconate suppresses cytotoxic CD8(+) T cells and promotes tumour growth","volume":"4","author":"Zhao","year":"2022","journal-title":"Nature Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1480","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2079182","article-title":"Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer","volume":"11","author":"Zheng","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1485","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105367","article-title":"Novel selective hexokinase 2 inhibitor Benitrobenrazide blocks cancer cells growth by targeting glycolysis","volume":"164","author":"Zheng","year":"2021","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1490","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202208103","article-title":"mTORC1 beyond anabolic metabolism: Regulation of cell death","volume":"221","author":"Zhu","year":"2022","journal-title":"The Journal of Cell Biology"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1495","article-title":"O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation","volume":"120","author":"Zhu","year":"2023","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1500","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1016\/j.ymthe.2025.08.019","article-title":"Asparaginase enhances CAR-T cell antitumor immunity by asparagine metabolic reprogramming and central memory induction in ALL","volume":"33","author":"Zhu","year":"2025","journal-title":"Molecular Therapy"},{"issue":"1045\u20131060","key":"10.1016\/j.pharmthera.2026.109109_bb1505","article-title":"Cancer cell-derived arginine fuels polyamine biosynthesis in tumor-associated macrophages to promote immune evasion","volume":"43","author":"Zhu","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2026.109109_bb1510","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s42255-020-0226-5","article-title":"Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours","volume":"2","author":"Zhu","year":"2020","journal-title":"Nature Metabolism"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:55:39Z","timestamp":1794412539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826001361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":315,"alternative-id":["S0163725826001361"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109109","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting metabolic reprogramming in cancer: Past, present, and future","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109109"}}